Abstract:AIM:To construct and evaluate the functionality of a choanoid-fluidized bed bioreactor (CFBB) based on microencapsulated immortalized human hepatocytes. METHODS:Encapsulated hepatocytes were placed in the constructed CFBB and circulated through Dulbecco's Modified Eagle's Medium (DMEM) for 12 h, and then through exchanged plasma for 6 h, and compared with encapsulated cells cultivated under static conditions in a spinner flask. Levels of alanine aminotransferase (ALT) and albumin were used to evaluate the CFBB during media circulation, whereas levels of ALT, total bilirubin (TBil), and albumin were used to evaluate it during plasma circulation. Mass transfer and hepatocyte injury were evaluated by comparing the results from the two experimental conditions. In addition, the viability and microstructure of encapsulated cells were observed in the different environments. RESULTS:The bioartificial liver model based on a CFBB was verified by in vitro experiments. The viability of encapsulated cells accounting for 84.6% ± 3.7% in CFBB plasma perfusion was higher than the 74.8% ± 3.1% in the static culture group (P < 0.05) after 6 h. ALT release from cells was 29 ± 3.5 U/L vs 40.6 ± 3.2 U/L at 12 h (P < 0.01) in the CFBB medium circulation and static medium culture groups, respectively. Albumin secretion from cells was 234.2 ± 27.8 μg/1 × 10(7) cells vs 167.8 ± 29.3 μg/1 × 10(7) cells at 6 h (P < 0.01), 274.4 ± 34.6 μg/1 × 10(7) cells vs 208.4 ± 49.3 μg/1 × 10(7) cells (P < 0.05) at 12 h, in the two medium circulation/culture groups, respectively. Furthermore, ALT and TBil levels were 172.3 ± 24.1 U/L vs 236.3 ± 21.5 U/L (P < 0.05), 240.1 ± 23.9 μmol/L vs 241.9 ± 31.4 μmol/L (P > 0.05) at 6 h in the CFBB plasma perfusion and static plasma culture groups, respectively. There was no significant difference in albumin concentration between the two experimental plasma groups at any time point. The microstructure of the encapsulated hepatocytes remained healthier in the CFBB group compared with the static culture group after 6 h of plasma perfusion. CONCLUSION:The CFBB can function as a bioartificial liver based on a bioreactor. The efficacy of this novel bioreactor is promising for the study of liver failure.

Configuration of a new bioartificial liver support system and in vitro evaluation of its functions.

Construction of a novel bioartificial liver system and its functional evaluation in vitro

Functional Evaluation of a New Bioartificial Liver System in Vivo and in Vivo

Development of a Novel Artificial Liver Support System

Bioartificial liver system based on choanoid fluidized bed bioreactor improve the survival time of fulminant hepatic failure pigs.

Progress in bioreactors of bioartificial livers.

Experimental study of bioartificial liver with cultured human liver cells.

Advances in cell sources of hepatocytes for bioartificial liver.

Key Challenges to the Development of Extracorporeal Bioartificial Liver Support Systems

The Development of a New Bioartificial Liver and Its Application in 12 Acute Liver Failure Patients

Evaluation of Hydromechanical and Functional Properties of Diversion-Type Microcapsule-Suspension Bioreactor for Bioartificial Liver

Co-culture of Parenchymal and Non-Parenchymal Liver Cells and Non-Liver-derived Cells

Function of A New Internal Bioartificial Liver: an in Vitro Study

Primary clinical study of a novel bioartificial liver combined with liver transplantation in patients with liver failure

Evaluation of a Novel Choanoid Fluidized Bed Bioreactor for Future Bioartificial Livers.

Bioartificial Liver Devices: Perspectives on the State of the Art

Efficacy of Fluidized Bed Bioartificial Liver in Treating Fulminant Hepatic Failure in Pigs: A Metabolomics Study

Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes

[Establishment and Significance of an Extracorporeal Bioartificial Liver Support System].

Integration of single-layer skin hollow fibers and scaffolds develops a three-dimensional hybrid bioreactor for bioartificial livers

Bioinspired Artificial Liver System with hiPSC‐Derived Hepatocytes for Acute Liver Failure Treatment